Hims & Hers Health (HIMS) Income from Continuing Operations (2019 - 2026)
Hims & Hers Health (HIMS) posted Income from Continuing Operations of 92115000.0 for Q1 2026, down 547.14% sequentially from 20601000.0 in Q4 2025, and down 286.15% YoY from 49485000.0 in Q1 2025.
Hims & Hers Health (HIMS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Hims & Hers Health has reported Income from Continuing Operations for 8 years, with the latest figure at 92115000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 286.15% year-over-year to 92115000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13235000.0 (down 108.05% YoY) and the FY2025 annual result came in at 128365000.0, up 1.85% from the prior year.
- Income from Continuing Operations retreated to 92115000.0 in Q1 2026 per HIMS's latest filing, from 20601000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 75588000.0 in Q3 2024 and troughed at 92115000.0 in Q1 2026.
- A 5-year average of 4297882.35 and a median of 1245000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations surged 1990.36% in 2024, then plunged 286.15% in 2026.
- Over 5 years, Income from Continuing Operations stood at 10907000.0 in 2022, then surged by 111.41% to 1245000.0 in 2023, then soared by 1990.36% to 26025000.0 in 2024, then retreated by 20.84% to 20601000.0 in 2025, then sank by 547.14% to 92115000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 92115000.0, 20601000.0, and 15774000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Hims & Hers Health | 7.42 Bn | 6.57 Bn | 480.80 Mn | -86.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -86.29 Mn |
| Mar 31, 2026 | -92.12 Mn |
| Dec 31, 2025 | 20.60 Mn |
| Sep 30, 2025 | 15.77 Mn |
| Jun 30, 2025 | 42.51 Mn |
| Mar 31, 2025 | 49.49 Mn |
| Dec 31, 2024 | 26.03 Mn |
| Sep 30, 2024 | 75.59 Mn |
| Jun 30, 2024 | 13.30 Mn |
| Mar 31, 2024 | 11.13 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | -7.57 Mn |
| Jun 30, 2023 | -7.16 Mn |
| Mar 31, 2023 | -10.07 Mn |
| Dec 31, 2022 | -10.91 Mn |
| Sep 30, 2022 | -18.84 Mn |
| Jun 30, 2022 | -19.68 Mn |
| Mar 31, 2022 | -16.25 Mn |
| Dec 31, 2021 | -31.16 Mn |
| Sep 30, 2021 | -15.94 Mn |